SGMO vs. ABCL

The year-to-date returns for both investments are quite close, with SGMO having a -31.35% return and ABCL slightly higher at -30.72%.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Sangamo Therapeutics, Inc. (SGMO) and AbCellera Biologics Inc. (ABCL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current SGMO Sharpe Ratio is 0.23, which is higher than the ABCL Sharpe Ratio of -0.75. The chart below compares the historical Sharpe Ratios of SGMO and ABCL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither SGMO nor ABCL has paid dividends to shareholders.

The maximum SGMO drawdown since its inception was -99.40%, roughly equal to the maximum ABCL drawdown of -96.72%. Use the drawdown chart below to compare losses from any high point for SGMO and ABCL. For additional features, visit the drawdowns tool.

Sangamo Therapeutics, Inc. (SGMO) has a higher volatility of 28.04% compared to AbCellera Biologics Inc. (ABCL) at 21.90%. This indicates that SGMO's price experiences larger fluctuations and is considered to be riskier than ABCL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Sangamo Therapeutics, Inc. and AbCellera Biologics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.